Repositioning Candidate Details
| Candidate ID: | R0854 |
| Source ID: | DB05732 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Strontium malonate |
| Synonyms: | -- |
| Molecular Formula: | C3H2O4Sr |
| SMILES: | [Sr++].[O-]C(=O)CC([O-])=O |
| Structure: |
|
| DrugBank Description: | Strontium malonate is being developed as a novel orally available pharmaceutical for the treatment and prevention of osteoporosis. It is being developed by Osteologix Inc. |
| CAS Number: | 183133-72-4 |
| Molecular Weight: | 189.67 |
| DrugBank Indication: | Investigated for use/treatment in osteoporosis. |
| DrugBank Pharmacology: | Strontium is known to have a positive effect on bone by concomitantly increasing bone formation while decreasing bone resorption thereby providing a sustained skeletal benefit. |
| DrugBank MoA: | -- |
| Targets: | -- |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I15 | 1290 | Bone disease | A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function. http://en.wikipedia.org/wiki/Bone_disease | disease of anatomical entity/ musculoskeletal system disease/connective tissue disease | Details |